Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Price:
14.86 AUD
Market Closed
Updated:
May 5, 2024
Clinuvel Pharmaceuticals Ltd
Operating Income
|
Clinuvel Pharmaceuticals Ltd
Operating Income Peer Comparison
Comparables:
IMM
MSB
CSL
TLX
PYC
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$50.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Operating Income
-AU$46.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-13%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$55.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$17.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$21.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-17%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Operating Income?
Operating Income
50.8m
AUD
50.8m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Operating Income amounts to 50.8m AUD.
What is Clinuvel Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
27%
27%
Over the last year, the Operating Income growth was 18%. The average annual Operating Income growth rates for Clinuvel Pharmaceuticals Ltd have been 36% over the past three years , 27% over the past five years .
You don't have any saved screeners yet
